Leading the future of radioimmunotherapy for cancer treatment

Leading the future of radioimmunotherapy for cancer treatment

Our CEO, Professor Marika Nestor discusses advancing cancer treatment through radioimmunotherapy in a new interview ahead of her presentation at Antibody Engineering & Therapeutics. The interview highlights Akiram’s recent milestone: the approval of a Phase 1 clinical trial for 177Lu-AKIR001, a novel radiolabeled antibody targeting cancers with high CD44v6 expression, including head and neck squamous…

She is creating brilliant chances for cancer patients

She is creating brilliant chances for cancer patients

Radiopharmaceuticals that fight cancer are on the rise and Marika Nestor is doing everything she can to contribute to their development. An antibody from her lab offers hope for a future treatment for those affected by anaplastic thyroid cancer, a currently incurable form of cancer. Read the full news item from Uppsala University here (in…

Latest DDD-exit: Radioactive antibody for treatment of aggressive cancer

Latest DDD-exit: Radioactive antibody for treatment of aggressive cancer

A new antibody might be the first effective treatment for Anaplastic thyroid cancer (ATC), a very aggressive cancer type with a median survival of only 4-5 month even with available treatments. The radiolabeled antibody is the result of a four-year long successful collaboration between SciLifeLab researcher Marika Nestor (Uppsala University) and the SciLifeLab Drug Discovery…